{"id":801541,"date":"2025-01-16T08:10:09","date_gmt":"2025-01-16T13:10:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/"},"modified":"2025-01-16T08:10:09","modified_gmt":"2025-01-16T13:10:09","slug":"sinovac-issues-statement-regarding-privy-council-judgment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/","title":{"rendered":"SINOVAC Issues Statement Regarding Privy Council Judgment"},"content":{"rendered":"

<\/p>\n

SINOVAC Issues Statement Regarding Privy Council Judgment<\/b><\/p>\n

BEIJING–(BUSINESS WIRE<\/a>)–
\nSinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company\u2019s Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week.<\/p>\n

\nSINOVAC\u2019s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC\u2019s significant value for the benefit of all shareholders.<\/p>\n

\nSince the 2018 Annual General Meeting, the Company has a strong track-record of creating tremendous value for all shareholders, having implemented several innovative, life-saving, and value-creating initiatives, including SINOVAC\u2019s leading role in combating the global COVID-19 pandemic delivering 2.9 billion doses or 22% of total global vaccination in the pandemic period.<\/p>\n

About SINOVAC<\/b><\/p>\n

\nSinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.<\/p>\n

\nSINOVAC\u2019s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.<\/p>\n

\nThe COVID-19 vaccine, CoronaVac\u00ae<\/sup>, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive\u00ae<\/sup>, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive\u00ae<\/sup>, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC\u2019s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.<\/p>\n

\nSINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1\u00ae<\/sup>, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu\u00ae<\/sup>, to the Chinese government stockpiling program.<\/p>\n

\nSINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.<\/p>\n

\nFor more information, please visit the Company\u2019s website at www.sinovac.com<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250116121834\/en\/<\/a><\/span><\/p>\n

\nSinovac Biotech Ltd.
\n
Helen Yang
\n
Tel: +86-10-8279 9779
\n
Email: ir@sinovac.com<\/a><\/p>\n

KEYWORDS:<\/b> China Europe United Kingdom Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Health Infectious Diseases Legal Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

SINOVAC Issues Statement Regarding Privy Council Judgment BEIJING–(BUSINESS WIRE)– Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company\u2019s Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week. SINOVAC\u2019s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC\u2019s significant value for the benefit of all shareholders. Since … <\/p>\n

Continue reading “SINOVAC Issues Statement Regarding Privy Council Judgment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801541","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SINOVAC Issues Statement Regarding Privy Council Judgment BEIJING–(BUSINESS WIRE)– Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company\u2019s Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week. SINOVAC\u2019s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC\u2019s significant value for the benefit of all shareholders. Since … Continue reading "SINOVAC Issues Statement Regarding Privy Council Judgment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T13:10:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SINOVAC Issues Statement Regarding Privy Council Judgment\",\"datePublished\":\"2025-01-16T13:10:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/\"},\"wordCount\":438,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/\",\"name\":\"SINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-01-16T13:10:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sinovac-issues-statement-regarding-privy-council-judgment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SINOVAC Issues Statement Regarding Privy Council Judgment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/","og_locale":"en_US","og_type":"article","og_title":"SINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk","og_description":"SINOVAC Issues Statement Regarding Privy Council Judgment BEIJING–(BUSINESS WIRE)– Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy Council also ruled that the Company\u2019s Rights Agreement is invalid. The ruling will take effect after entry of a court order expected within a week. SINOVAC\u2019s outgoing Board members are committed to ensuring a smooth transition with the new Board members and to preserving SINOVAC\u2019s significant value for the benefit of all shareholders. Since … Continue reading \"SINOVAC Issues Statement Regarding Privy Council Judgment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-16T13:10:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SINOVAC Issues Statement Regarding Privy Council Judgment","datePublished":"2025-01-16T13:10:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/"},"wordCount":438,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/","name":"SINOVAC Issues Statement Regarding Privy Council Judgment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-01-16T13:10:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250116121834r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sinovac-issues-statement-regarding-privy-council-judgment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SINOVAC Issues Statement Regarding Privy Council Judgment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801541"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801541\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}